Itovebi (Inavolisib) is a prescription oral medication classified as a PI3Kα inhibitor. It is a targeted therapy designed to treat certain types of advanced breast cancer by blocking a specific protein (PI3Kα) that helps cancer cells grow and spread, especially when a particular genetic mutation (PIK3CA) is present.
Inavolisib
Generic Name/API:Inavolisib
Packaging:A pack containing 28 tablets
Storage:Store at 20°C to 25°C
Dosage:9 mg orally once daily with or without food.
Strength:Tablets: 3 mg and 9 mg
Indication:Inavolisib (Itovebi) is a highly selective inhibitor of PI3Kδ (phosphoinositide 3-kinase delta), an enzyme that plays a crucial role in the growth and survival of immune cells, particularly B cells.
Inavolisib (Itovebi) is a kinase inhibitor indicated in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy
Strength:
Tablets: 3 mg and 9 mg
Dosage:
9 mg orally once daily with or without food.
Dose Reduction for Adverse Reaction :
| Dose Level | Dosage and Schedule |
| Recommended Starting | 9mg daily |
| First dose Reduction | 6mg daily |
| Second Dose Reduction | 3mg daily |
Adverse reactions:
- Hyperglycemia- Increased fasting glucose occurred in 85% of patients treated with Itovebi, including 22% of patients with Grade 2 (FPG > 160 to 250 mg/dL), 12% with Grade 3 (FPG > 250 to 500 mg/dL), and 0.6% with Grade 4 (FPG > 500 mg/dL) events
- Stomatitis- Stomatitis occurred in 51% of patients treated with Itovebi in combination with palbociclib and fulvestrant, including Grade 3 events in 6% of patients. The median time to first onset was 13 days (range: 1 to 610 days).
- Diarrhea – Diarrhea occurred in 48% of patients treated with Itovebi in combination with palbociclib and fulvestrant, including Grade 3 events in 3.7% of patients. The median time to first onset was 15 days (range: 2 to 602 days).
Storage:
- 20°C to 25°C
- Protect from light
- Hyperglycemia (High Blood Sugar): Itovebi can significantly increase blood sugar levels. This is a major concern, especially for patients with pre-existing diabetes or those at risk.
- Diarrhea: Diarrhea is a common side effect of Itovebi and can be severe.
- Stomatitis (Mouth Sores): Itovebi can cause inflammation of the mouth and ulcers
- Rash: Itovebi can cause various skin rashes, some of which may be severe.
- Severe Hypersensitivity Reactions: Although rare, severe allergic reactions can occur.
- Embryo-Fetal Toxicity: Itovebi can harm a developing fetus.
FAQ
What type of cancer does Itovebi treat?
Itovebi is specifically approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced or metastatic breast cancer. It is typically used in patients who have progressed on or after at least one line of endocrine-based therapy for their advanced disease.
How does Itovebi work?
Itovebi works by selectively inhibiting the alpha isoform of phosphatidylinositol 3-kinase (PI3Kα). The PI3K pathway is often overactive in various cancers due to mutations, particularly in the PIK3CA gene. By blocking PI3Kα, Itovebi helps to suppress cell growth and survival signals in cancer cells, thereby slowing down tumor progression.
What are the most common side effects of Itovebi?
Common side effects can include hyperglycemia (high blood sugar), rash, diarrhea, stomatitis (mouth sores), fatigue, and nausea. Other side effects may include abdominal pain, decreased appetite, and certain laboratory abnormalities. Your healthcare team will monitor you closely for these and other potential side effects.
Is Itovebi used alone, or in combination with other drugs?
Itovebi is typically used in combination with another medication called fulvestrant, which is an endocrine therapy. This combination aims to provide a more comprehensive approach to treating HR+, HER2- breast cancer, especially when a PIK3CA mutation is present.
What is the cost of Itovebi (Inavolisib) tablets in India?
The cost of Itovebi (Inavolisib) tablets in India varies as it is not commercially available locally and must be imported through authorized channels. Pricing depends on supplier availability, import duties and global currency exchange rates. For the most updated cost, contact 24/7QualityMeds at +91 9967979080.
How to buy Itovebi (Inavolisib) online in India?
To buy Itovebi (Inavolisib) tablets online in India safely and at a genuine price, contact 24/7QualityMeds. We assist patients with legal import procedures, prescription verification, sourcing from trusted suppliers and ensuring secure delivery across India.
